Pregnancy outcomes amongst multiple sclerosis females with third trimester natalizumab use

ConclusionsComplications following natalizumab administration during the second and third trimester of pregnancy occurred in 33% of newborns. However, did not result in mortality or morbidity. Dose alterations during the third trimester, pre-delivery umbilical cord sampling and IVIG administration may reduce hematological effects on newborns. Prospective studies with larger numbers of patients are required to provide further evidence regarding the safety of Natalizumab use in pregnancy.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research

Related Links:

Conclusions: Treatment outcome of PRCA depended upon the causes and the types of treatment, and the burden of RBC transfusion was very high in patients with ESA and thymoma-associated PRCA. PMID: 32257434 [PubMed]
Source: Anemia - Category: Hematology Tags: Anemia Source Type: research
This study aimed to study the endoscopic yield, appropriateness, and complications of pediatric endoscopy performed by adult gastroenterologists in an adult endoscopic suite. Methods: This a retrospective study in which records of all the patients less than 18 years of age who underwent endoscopy in the last 5 years were studied. The indications of endoscopy in children were categorized as appropriate or inappropriate per the latest guidelines by American Society for Gastrointestinal Endoscopy and North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. Positive endoscopic yield was defined as t...
Source: Clinical Endoscopy - Category: Gastroenterology Tags: Clin Endosc Source Type: research
In this study, we investigated the protective effects of epimedium polysaccharide (EPS), a natural compound with antioxidant and immune-enhancing potency, on aplastic anemia induced by benzene exposure in mice. Male CD-1 mice were randomly divided into five groups including control, BZ (880 mg/kg), LE (EPS low-dose, 20 mg/kg + BZ), ME (EPS middle-dose, 100 mg/kg + BZ), and HE (EPS high-dose, 200 mg/kg + BZ) groups. Animals were exposed to BZ by subcutaneous injection in the presence or absence of EPS via oral administration. All mice were treated 3 times...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
(Elsevier) Approximately 5% of women experience two or more miscarriages, a condition known as recurrent pregnancy loss (RPL). Although genetic testing is important for evaluating RPL, current tests have revealed shortcomings in clinical practice. A report in The Journal of Molecular Diagnostics describes a new high-resolution melting analysis-based test that is accurate, rapid, cheap, and easy to perform. When used prior to other tests, it improved cost-effectiveness by 30%, an important consideration in areas with limited healthcare resources.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Abstract Background: Preeclampsia is a major cause of pregnancy-related maternal, fetal, and neonatal morbidities and mortalities. We aimed to review the effect of maternal preeclampsia on the hematological profile of newborns in the Qatari population. Methods: In this case-control study, we reviewed data and complete blood count results of neonates born to Qatari women diagnosed of preeclampsia in 2017 in comparison with data of a control group. Statistical analysis was done using unpaired t-test, chi-square test, and logistic regression analysis. Results: A total of 108 neonates of women with preeclamp...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
Abstract Methods: A retrospective follow-up study was conducted among clients on ART from 2012 to 2017. Data were collected using checklists. The Kaplan-Meier curve was employed to compare survival rates. The Cox proportional hazard model was applied to identify predictors of time to development of anemia. Results: A total of 490 ART patients were followed. The overall incidence of anemia was 27/100 person-years. The incidence was highest in the second year (18.7/100 PY) of starting ART when compared with the first year (13.8/100 PY) and third year (18.1/100 PY) of ART initiation. The independent predictors s...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
We report here a 6-year-old Syrian boy with unexplained microcytic anemia since one year of age. Genetic analysis of the TMPRSS6 gene revealed a novel homozygous nonsense mutation in exon 3 (c.234C> G; p.Y78* or p.Tyr78*). In the presence of hypochromic microcytic anemia accompanied by atypical iron parameters not in accordance with classic IDA, and inadequate response to iron therapy, IRIDA should be remembered in the differential diagnosis. PMID: 32253873 [PubMed - in process]
Source: The Turkish Journal of Pediatrics - Category: Pediatrics Authors: Tags: Turk J Pediatr Source Type: research
Publication date: Available online 8 April 2020Source: NeuroImageAuthor(s): Dinesh K. Sivakolundu, Kathryn L. West, Mark Zuppichini, Monroe P. Turner, Dema Abdelkarim, Yuguang Zhao, Jeffrey S. Spence, Hanzhang Lu, Darin T. Okuda, Bart Rypma
Source: NeuroImage - Category: Neuroscience Source Type: research
Conclusions: Complications following natalizumab administration during the second and third trimester of pregnancy occurred in 33% of newborns. However, did not result in mortality or morbidity. Dose alterations during the third trimester, pre-delivery umbilical cord sampling and IVIG administration may reduce hematological effects on newborns. Prospective studies with larger numbers of patients are required to provide further evidence regarding the safety of Natalizumab use in pregnancy.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Objective:To assess hematological abnormalities (HA) and MS disease activity after exposure to natalizumab (NTZ) during pregnancy in women with highly active multiple sclerosis (MS).Background:Severe rebound after NTZ withdrawal might also occur during pregnancy, but anemia and thrombocytopenia will occure in 75% of newborns after NTZ exposure after the 30th gestational week. The best timepoint when to stop NTZ during pregnancy in women with aggressive MS is not known.Design/Methods:In this prospective, observational case series we compare relapses during pregnancy and HA in newborns of mothers exposed to NTZ less than 24 weeks (
Source: Neurology - Category: Neurology Authors: Tags: MS and CNS Inflammatory Disease Poster Discussion Session Source Type: research
More News: Anemia | Hematology | Laboratory Medicine | Multiple Sclerosis | Neurology | Pregnancy | Study | Thrombocytopenia | Tysabri